User menu

Absolute Bioavailability of Mianserin Tablets and Solution in Healthy Humans

Bibliographic reference Timmer, CJ. ; Pourbaix, S. ; Desager, Jean-Pierre ; Sclavons, Michel ; Harvengt, C.. Absolute Bioavailability of Mianserin Tablets and Solution in Healthy Humans. In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 10, no. 4, p. 315-323 (1985)
Permanent URL
  1. Brogden R.N., Heel R.C., Speight T.M. and Avery G.S. (1978): Mianserin : a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs16, 273–301.
  2. Van Riezen H., Pinder R.M., Nickolson V.J., Hobbelen P., Zayed I. and Van der Veen F. (1981): Mianserin. In: Goldberg M.E. (ed.) Pharmacological and biochemical properties of drug substances, vol. 3. American Pharmaceutical Association, Washington, 56–93.
  3. Jansen H. (1978): Contribution to workshop on the clinical pharmacology and efficacy of mianserin. Br. J. Clin. Pharmacol.,5, 91S-99S.
  4. Vink J. and Van Hal H.J.M. (1980): Simplified method for determination of the tetracyclic antidepressant mianserin in human plasma using gas chromatography with nitrogen detection. J. Chromatogr.,181, 25–31.
  5. Rowland M. and Tucker G. (1980): Symbols in pharmacokinetics. J. Pharm. Pharmacokinet. Biopharm.,8, 497–507.
  6. Wijnand H.P. and Timmer C.J. (1979): Curve-fitting and modeling in pharmacokinetics: all programs are equal, but some programs are more equal than others. J. Pharmacokinet. Biopharm.,7, 681–684.
  7. Boxenbaum H.G., Riegelman S. and Elashoff R.M. (1974): Statistical estimation in pharmacokinetics. J. Pharmacokinet. Biopharm.,2, 123–147.
  8. Wijnand H.P. and Timmer C.J., (1983): Mini-computer programs for bioequivalence testing of pharmaceutical drug formulations in two-way cross-over studies. Comput. Programs. Biomed.,17, 73–88.
  9. Westlake W.J. (1972): Use of confidence intervals in analysis of comparative bioavailability trials. J. Pharm. Sci,61, 1340–1341.
  10. Rodda Bruce E, Davis Robert L, Determining the probability of an important difference in bioavailability, 10.1038/clpt.1980.157
  11. Fluehler H., Hirtz J. and Moser H.A. (1981): An aid to decision-making in bioequivalence assessment. J. Pharmacokinet. Biopharm.,9, 235–243.
  12. Maguire K.P., Norman T.R., Burrows G.D. and Scoggins B.A. (1982): A pharmacokinetic study of mianserin. Eur. J. Clin. Pharmacol.,21, 517–520.
  13. Hrdina Pavel D, Lapierre Yvon D, Mclntosh Brent, Oyewumi L K, Mianserin kinetics in depressed patients, 10.1038/clpt.1983.103
  14. Tozer T.N. (1981): Concepts basic to pharmacokinetics. Pharmacol. Ther.,12, 109–132.
  15. Gibaldi M., Boyes R.N. and Feldman S. (1971): Influence of first-pass effect on availability of drugs on oral administration. J. Pharm. Sci.,60, 1338–1340.